Cancers & treatments·Regimen libraryInduction

Gemcitabine + cisplatin (nasopharyngeal)

Checked 2026-09-09

Locoregionally advanced nasopharyngeal carcinoma, induction before chemoradiation; recurrent or metastatic disease with toripalimab

One cycle

every 21 days × 3 · about 9 weeks in total

21-day cycle × 3 induction (6 with toripalimab in metastatic disease) (about 9 weeks)Intravenous

Components

Drug	Dose	Route	Days
Gemcitabine Nucleoside analogue (deoxycytidine)	1,000 mg/m²	IV	D1, 8
Cisplatin Cytotoxic chemotherapy (platinum)	80 mg/m²	IV	D1
Toripalimab (recurrent or metastatic, JUPITER-02) Monoclonal antibody (anti-PD-1)	240 mg	IV	D1

Cycles

3 induction (6 with toripalimab in metastatic disease)

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Not routine

Used in

Nasopharyngeal carcinoma

Trials

JUPITER-02

Products

GemcitabineCisplatinToripalimab

Source

Zhang, NEJM 2019 (induction GP)

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

High-dose cisplatin chemoradiation

Locally advanced head and neck squamous cell carcinoma, definitive or postoperative (positive margins or extranodal extension)

every 21 days × 3

All regimens CHOP →